A Vaccine against Streptococcus pyogenes.

Streptococcus pyogenes causes severe, invasive infections such as the sequelae associated with acute rheumatic fever, rheumatic heart disease, acute glomerulonephritis, uncomplicated pharyngitis, and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different...

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal of Cardiovascular Drugs Vol. 13; no. 1; pp. 1 - 5
Autores principales: Guilherme, Luiza, Ferreira, Frederico, Köhler, Karen, Postol, Edilberto, Kalil, Jorge
Formato: pictorial tables/charts Journal Article
Publicado: Springer Nature Feb2013
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104314243&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104314243
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11753277
        G7S
      jtl: American Journal of Cardiovascular Drugs
      issn: 11753277
      maglogo: N
    pubinfo:
      dt: Feb2013
      vid: 13
      iid: 1
      pid: 87227
      pub: Springer Nature
    artinfo:
      ui:
        104314243
        85456450
        10.1007/s40256-013-0005-8
        NLM23355360
        104314243
      ppf: 1
      ppct: 4
      formats:
      tig:
        atl: A Vaccine against Streptococcus pyogenes.
      aug:
        au:
          Guilherme, Luiza
          Ferreira, Frederico
          Köhler, Karen
          Postol, Edilberto
          Kalil, Jorge
      sug:
        subj:
          Streptococcal Infections Prevention and Control
          Streptococcal Infections Immunology
          Bacterial Vaccines
          Streptococcus
          Models, Biological
          Peptides Immunology
          Rheumatic Fever Prevention and Control
          Rheumatic Heart Disease Prevention and Control
      ab: Streptococcus pyogenes causes severe, invasive infections such as the sequelae associated with acute rheumatic fever, rheumatic heart disease, acute glomerulonephritis, uncomplicated pharyngitis, and pyoderma. Efforts to produce a vaccine against S. pyogenes began several decades ago, and different models have been proposed. We have developed a vaccine candidate peptide, StreptInCor, comprising 55 amino acid residues of the C-terminal portion of the M protein and encompassing both the T- and B-cell protective epitopes. The present article summarizes data from the previous 5 years during which we tested the immunogenicity and safety of StreptInCor in different animal models. We showed that StreptInCor overlapping peptides induced cellular and humoral immune responses of individuals bearing different HLA class II molecules. These results are consistent with peptides that have a universal vaccine epitope. The tridimensional molecular structure of StreptInCor was elucidated by nuclear magnetic resonance spectroscopy, which showed that its structure is composed of two microdomains linked by an 18-residue α-helix. Additionally, we comprehensively evaluated the structural stability of the StreptInCor peptide in different physicochemical conditions using circular dichroism. Additional experiments were performed with inbred, outbred, and HLA class II transgenic mice. Analysis of several organs of these mice showed neither deleterious nor autoimmune reactions even after a long period of vaccination, indicating that the StreptInCor candidate peptide could be considered as an immunogenic and safe vaccine.
      pubtype: Academic Journal
      doctype:
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N